ClinicalTrials.gg
WithdrawnNCT01423240RESOLVE2Updated Dec 13, 2012

Major Depressive Disorder With Mixed Features

A Phase 3 interventional study of Lurasidone 20 mg and Lurasidone 60 mg in Major Depressive Disorder, sponsored by Sumitomo Pharma America, Inc.. Withdrawn at 27 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-12-13.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
1,286th of 1,323
0 · median 70
Started
2012
with 63 others
Phase 3
240 of 1,500
21 open now
Registered
506th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 1,286th largest by enrollment of the 1,323 interventional ones that give a count, is one of 64 that started in 2012, is one of 240 in phase 3, and was the 506th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Depression
  • Lurasidone
  • Latuda
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject provides written and is willing and able to comply with the protocol in the opinion of the Investigator.

Subject is 18 to 75 years of age, inclusive. Subject has MDD (diagnosed by , and confirmed by the Structured Clinical Interview for DSM-IV Disorders - Clinical Trial version [SCID-CT]).

Subject is currently experiencing a major depressive episode (diagnosed by DSM-IV-TR; at least 2 weeks in duration) AND two or three of the following manic symptoms occurring on most days over at least the last 2 weeks (confirmed by the SCID-CT modified for Study D1050305):

  • Elevated, expansive mood
  • Inflated self-esteem or grandiosity
  • More talkative than usual or pressure to keep talking
  • Flight of ideas or subjective experience that thoughts are racing
  • Increase in energy or goal-directed activity (either socially, at work or school, or sexually)
  • Increased or excessive involvement in activities that have a high potential for painful consequences (e.g., engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments)
  • Decreased need for sleep (feeling rested despite sleeping less than usual; to be contrasted from insomnia) Subject has a rater-administered Montgomery-Asberg Depression Rating Scale (MADRS) total score of ≥ 26 at screening and both a rater-administered and self-rated (administered by computer) MADRS total score ≥ 26 at baseline.

Exclusion criteria

Exclusion Criteria:

Subject has Axis I or Axis II diagnosis other than MDD that has been the primary focus of treatment within the 3 months prior to screening Subject answers "yes" to "Suicidal Ideation" Item 4 or 5 on the C-SSRS (at time of evaluation) at screening or baseline visit.

Subject has attempted suicide within the past 3 months. Subject has a lifetime history of any bipolar I manic or mixed manic episode. Subject has any abnormal laboratory parameter at screening that indicates a medical condition as determined by the Investigator.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Lurasidone 20 mg

    Drug: Lurasidone 20 mg

  • Experimental
    Lurasidone 60 mg

    Drug: Lurasidone 60 mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Lurasidone 20 mg once daily orally in the evening

    Also known as: Latuda

  • Lurasidone 60 mg once daily orally in the evening

    Also known as: Latuda

  • DrugPlacebo

    Placebo once daily orally in the evening

06

What researchers measure

Primary outcomes

  1. MADRS

    Mean change from baseline in MADRS total score after 6 weeks of treatment

    Time frame: 6 weeks

Secondary outcomes

  1. CGI-S

    Global severity assessed by the CGI-S score (depression)

    Time frame: 6 weeks

07

Study locations

27 sites
  • Birmingham Research Group
    Birmingham, Alabama 35216, United States
  • Sun Valley Behavioral Medical
    Imperial, California 92251, United States
  • Synergy Clinical Research Center
    National City, California 91950, United States
  • Excell Research
    Oceanside, California 92056, United States
  • Pacific Clinical Research Medical Group
    Orange, California 92868, United States
  • SMRI
    Sherman Oaks, California 91403, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Florida Research Center
    Maitland, Florida 32751, United States
  • University of Miami, Miller School
    Miami, Florida 33136, United States
  • Miami Research
    Miami, Florida 33143, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • Comprehensive NeuroScience Inc.
    Atlanta, Georgia 30328, United States
  • Hawaii Clinical Research Center
    Honolulu, Hawaii 86813, United States
  • Psychiatric Medicine Associates
    Skokie, Illinois 60076, United States
  • Goldpoint Clinical Research
    Indianapolis, Indiana 46260, United States
  • CRI Worldwide
    Willingboro, New Jersey 08054, United States
  • Montefiore Medical Center; Anxiety & Depression Clinic; Dept. of Psychiatry
    Bronx, New York 10467, United States
  • Medical & Behavioral Health Research
    New York, New York 10023, United States
  • New Hope Clinical Research
    Hickory, North Carolina 28601, United States
  • Sooner Clinical Research
    Oklahoma City, Oklahoma 73112, United States
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18104, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Harry Croft and Associates
    San Antonio, Texas 78229, United States
  • University of Texas Health Science Center
    San Antonio, Texas 78229, United States
  • Grayline Clinical Drug Trials
    Wichita Falls, Texas 76309, United States
  • Department of Psychiatry, University of Utah Health Sciences Center
    Salt Lake City, Utah 84132, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
08

References and documents

Publications

  • Goldberg JF, Siu C, Mao Y, Tsai J, Pikalov A, Calabrese JR, Loebel A. Major depressive disorder with mixed features and treatment response to lurasidone: A symptom network model. J Affect Disord. 2020 Dec 1;277:1045-1054. doi: 10.1016/j.jad.2020.08.048. Epub 2020 Aug 26. PubMed 33065813 ↗
  • Suppes T, Silva R, Cucchiaro J, Mao Y, Targum S, Streicher C, Pikalov A, Loebel A. Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study. Am J Psychiatry. 2016 Apr 1;173(4):400-7. doi: 10.1176/appi.ajp.2015.15060770. Epub 2015 Nov 10. PubMed 26552942 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2011
First posted
Aug 25, 2011
Start
Jan 2012
Primary completionEst.
Dec 2012
CompletionEst.
Dec 2012
Last update
Dec 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01423240
Responsible party
Sponsor
First posted
Aug 25, 2011
Start date
Jan 2012
Primary completion
Dec 2012 (estimated)
Completion
Dec 2012 (estimated)
Last update
Dec 13, 2012

Study contacts

Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion